Treating Stage IV Breast Cancer: Who, What, Where and When?

Significant advances in systemic treatment options have positively impacted breast cancer survivorship. Patients of all subtypes are living longer than ever, rendering the optimal selection of who to treat with radiation whether for local control of the primary site, oligometastatic site, or oligoprogressive disease, an important choice that we make in daily clinical practice. Available literature is conflicting and confusing to interpret, with the different timing of treatments and selection of (or lack of) the Stage IV women for whom we would consider a more aggressive treatment. Many clinicians find themselves in the precarious position of discussing with multispecialty colleagues the difficult cases where the saying ‘absence of evidence is not evidence of absence’ applies. There is an increasing need to develop clinical guidelines and dialogue for decision making around this patient population, as none currently exist.

The activity is opened by Dr. Eileen Connolly who discusses the results of BR002 and CURB to give a brief review, including the limitations of the randomized data around the oligometastatic population. She also discusses some of the retrospective data that encourages oligometastatic treatment, helping to model a nuanced approach to this very heterogeneous patient population. Next, Dr. Seema Khan comprehensively reviews the literature for primary breast treatment in the context of metastatic disease, including the results of the trial for which she was PI, EA2108. Next, Dr. Michael Yan offers his take on how to practically approach treatment of the primary in stage IV patients, and how to incorporate response to systemic therapy and extent of oligometastases in the shared decision-making process with the patient. He also discusses the field and fractionation options available to us.

Topics:

  1. One Too Many? What We Know So Far About Oligometastatic Breast Cancer
    Eileen P. Connolly, MD, PhD
  2. Primary Source - Treating the Primary in Stage IV Patients
    Seema A. Khan, MD
  3. Dealer's Choice - Knowing When to Treat
    Michael Yan, MD, MPH
  4. Case Discussions / Q&A
    Julie C. Choi, MD - Moderator
    Full Panel

This activity is available from August 19, 2025, through 11:59 p.m. Eastern time on August 18, 2027. 

The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Stratify patients in a formulaic way, so that consistency in treatment decision making can be developed, while recognizing the unique needs of each patient and clinic; academic versus clinical. 
  • Synthesize the available data regarding treatment for both oligometastatic disease and the breast primary in the setting of metastatic disease. 
  • Know the most supported fractionation schemes for oligometastatic disease and primary breast disease. 

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
08/19/2025
Course expires: 
08/18/2027
Cost:
$149.00
Rating: 
0
  • Julie C. Choi, MD, is employed by Columbia University. 
  • Seema A. Khan, MD, is employed by Northwestern University Robert H. Lurie Comprehensive Cancer Center. 
  • Eileen P. Connolly, MD, PhD, is employed by Columbia University. Dr. Connolly receives grant/research funding from Merck and Eisai. Dr. Connolly owns stock and stock options in BMS. 
  • Michael Yan, MD, MPH, is employed by Princess Margaret Cancer Centre, University of Toronto. Dr. Yan receives compensation from Need, Inc. 

The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Activity Fees

This activity is included in the ASTRO Academy Subscription. To purchase the subscription beginning December 1, 2026, please go to the ASTRO Product Catalog.

ASTRO members and Academy subscribers must log in to the ASTRO Academy to view and receive the corresponding rate:

  • Academy Subscriber: $0
  • Member: $99
  • Member-in-Training / Student Member / Postdoctoral Fellow Member: $49
  • Nonmember: $149

Discounts
Please email ASTRO eLearning to inquire about the discounts below.

  • If you are an ASTRO member residing in a low- or lower-middle-income economy country, as identified by the World Bank, you can receive a 50% discount off the activity fee.
  • If you are an ASTRO member residing in an upper-middle-income economy country, as identified by the World Bank, you can receive a 25% discount off the activity fee.

Policies

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until the Activity expiration date, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Copyright of all aspects of ASTRO Academy Content, including recordings and/or reproductions of sessions, programs, presentations, discussions and other scheduled events (“ASTRO Academy Content”) is owned by ASTRO. Only ASTRO reserves the rights to all ASTRO Academy Content, including to digitize, modify, alter, edit, adapt, create derivative works, display, publicly perform, exhibit, transmit, broadcast, reproduce, exploit, sell, rent license, otherwise use, and permit others to use, such ASTRO Academy Content. Photographing, filming, taping, recording or any form of capture or reproduction in any medium of any aspect of ASTRO Academy Content, including, but not limited to the programs, presentations, material, sessions, and discussions, or on the Academy platform are strictly forbidden without written authorization from ASTRO.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.